MK-386, an inhibitor of 5α-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 5, 1997, Pages 1373-1377

  Schwartz, Jules I ^a   Tanaka, Wesley K ^a   Wang, Daniel Z ^a   Ebel, David L ^a   Geissler, Lori A ^a   Dallob, Aimee ^a   Hafkin, Barry ^b   Gertz, Barry J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Pharmaco International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7BETA DIMETHYL 4 AZACHOLESTAN 3 ONE; ALANINE AMINOTRANSFERASE; ANDROSTANEDIOL; ANDROSTANOLONE; ASPARTATE AMINOTRANSFERASE; AZASTEROID; FINASTERIDE; LUTEINIZING HORMONE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEADACHE; HORMONE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEBUM; SEMEN ANALYSIS; TESTOSTERONE BLOOD LEVEL;

EID: 0030982034     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.5.3912     Document Type: Article

References (44)

1. Ito T, Horton R. 1982 The source of plasma dihydrotestosterone in man. J Clin Invest. 3:1-25.
2. Martini L. 1982 The 5α-reduction of testosterone in the neuroendocrine structures: biochemical and physiologic implications. Endocr Rev. 3:1-25.
3. Wilson JD, Walker JD. 1969 The conversion of testosterone to 5α-androstane-17-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest. 48:371-379.
4. Wilson JD. 1970 The intranuclear metabolism of testosterone in the accessory organs of reproduction. Recent Prog Horm Res. 26:309-336.
5. Imperato-McGinley J, Guerrero L, Gautier T, et al. 1974 Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 186:1213-1215.
6. Walsh PC,. Madden JD, Harrod MJ, et al. 1974 Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 291:944-949.
7. Gormley GJ, Stoner E, Bruskewitz RC, et al. 1992 The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1185-1191.
8. Price VH. 1975 Testosterone metabolism in the skin. Arch Dermatol. 111:1496-1502.
9. Tenover JS. 1991 Prostates, pates, and pimples - the potential medical uses of steroid 5α-reductase inhibitors. Endocrinol Metab Clin North Am. 20:893-909.
10. Rittmaster RS. 1995 Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab. 80:2559-2563.
11. Bingham KD, Shaw DA. 1973 The metabolism of testosterone by human male scalp skin. J Endocrinol. 57:111-121.
12. Schweikert HU, Wilson JD. 1974 Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J Clin Endocrinol Metab. 38:811-819.
13. Schmidt JA, Schweikert HU. 1986 Testosterone and epitestosterone metabolism of single hairs in five patients with 5α-reductase-deficiency. Acta Endocrinol (Copenh). 113:588-592.
14. Andersson SR, Bishop RW, Russell DW. 1989 Expression cloning and regulation of steroid 5α-reductase, and enzyme essential for male sexual differentiation. J Biol Chem. 264:16249-16255.
15. Andersson S, Russell DW. 1990 Structure and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA. 87:3640-3644.
16. Andersson S, Berman DM, Jenkins EP, et al. 1991 Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354:159-161.
17. Jenkins EP, Andersson S, Imperato-McGinley, et al. 1992 Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest. 89:293-300.
18. Harris G, Azzolina B, Baginsky W, et al. 1992 Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc Natl Acad Sci USA. 89:10787-10791.
19. Rasmusson GH. 1987 Biochemistry and pharmacology of 5α-reductase inhibitors. In: Furr BJA, Wakeling AE, eds. Pharmacology and clinical uses of inhibitors of hormone secretion and action. London: Bailliere Tindall; 308-325.
20. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. 1993 Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Ivest. 92:903-910.
21. Tolman RL, Aster S, Bakshi RK, et al. 1995 4-Azasteroids as 5α-reductase inhibitors: identification of 4,7β-dimethyl-4-AZA-5α-cholestan-3-one (MK-386) as a scalp isozyme selective inhibitor. Eur J Med Chem. 30(Suppl)311s-216s.
22. McConnell JD, Wilson JD, George FW, et al. 1992 Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 74:505-508.
23. Gormley GJ, Stoner E, Rittmaster RS, et al. 1990 Effects of finasteride (MK-906), a 5α-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 67:1136-1141.
24. Schwartz J, Van Hecken A, De Schepper PJ, et al. 1996 Effect of MK-386, a novel inhibitor of type (1) 5α-reductase, alone and in combination with finasteride, on serum DHT (dihydrotestosterone) concentrations in men. J Clin Endocrinol Metab. 81:2942-2947.
25. Herman DJ, Davis IM, Wilson TH. 1996 Effects of GI 198745 (GG745), A novel 5-alpha reductase (5AR) inhibitor on dihydrotestosterone (DHT). Clin Pharmacol Ther. 59:192.
26. Thiboutot D, Harris G, Iles V, et al. 1995 Activity of the type 1 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 105:209-214.
27. Furuyama S, Mayes DH, Nugent CA. 1970 Radioimmune assay for plasma testosterone. Steroids. 16:415-428.
28. Dallob AL, Sadick NS, Unger W, et al. 1994 The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 79:703-706.
29. Pochi PE. 1982 Androgenic effects on human sebaceous glands. Arch Dermatol. 118:803-804.
30. Harris HH, Downing DT, Stewart ME, et al. 1983 Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol. 8:200-203.
31. Strauss JS, Kligman AM, Pochi PE. 1962 The effect of androgens and estrogens on human sebaceous glands. J Invest Dermatol. 39:139-155.
32. Pochi PE, Strauss JS. 1974 Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol. 62:191-201.
33. Imperato-McGinley J, Gautier T, Cai L-Q, Yee B, Epstein J, Pochi P. 1993 The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 76:524-528.
34. Eicheler W, Dreher M, Hoffmann R, et al. 1995 Immunohistochemical evidence for differenctial distribution of 5α-reductase isoenzymes in human skin. Br J Dermatol. 133:371-376.
35. George FW, Russell DW, Wilson JD. 1991 Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5α-reductase. Proc Natl Acad Sci USA. 88:8044-8047.
36. Horton R, Hawks D, Lobo R. 1986 3α-17β Androstanediol glucuronide in plasma: a marker of androgen action in idiopathic hirsutism. Br J Dermatol. 96:371-381.
37. Lookingbill DP, Egan N, Santen RJ, Demers LM. 1988 Correlation of serum 3α-androstanediol glucuronide with acne and chest hair density in men. J Clin Endocrinol Metab. 67:986-991.
38. Lookingbill D, Demers L, Tigelaar R, Shalita A. 1988 Effect of isotretinoin on serum levels of precursor and peripherally derived androgens in patients with acne. Arch Dermatol. 124:540-543.
39. Duffy DM, Legro RS, Chang L, Stanczyk, Lobo RA. 1995 Metabolism of dihydrotestosterone to 5alpha-androstane-3alpha,17beta-diol gluronide is greater in the peripheral compartment than in the splanchnic compartment. Fertil Steril. 64:736-739.
40. Miller JA, Wojnarowska FT, Dowd PM, et al. 1986 Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol. 114:705-716.
41. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. 1984 Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 111:209-214.
42. Greenwood R, Brummitt L, Burke B, et al. 1985 Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J 291:1231-1235.
43. Cunliffe WJ. 1982 Acne, hormones, and treatment. Br Med J. 285:912-913.
44. Pye RJ, Meyrick G, Pye MJ, et al. 1977 Effect of oral contraceptives on sebum excretion rate. Br Med J. 17:1581-1582.